Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00401726 · ClinicalTrials.gov registry record · Phase 4
Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program
A Phase 4 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 537
- Enrollment target
NCT00401726 is a Phase 4 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 537 participants.
The verdict
NCT00401726, a Phase 4 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 537 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of the Dialogues Time to Talk program in subjects treated with Venlafaxine Extended Release (ER). Dialogues Time to Talk Program is a patient management program, which aims to help patients achieve successful outcomes by reinforcing physician treatment efforts, providing feedback to treating physicians, and encouraging better physician-patient communications.
Interventions
- DRUG Venlafaxine ER
- BEHAVIORAL Dialogues Time to Talk Program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 537 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00401726
The ClinicalTrials.gov registry entry for NCT00401726 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 537 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Venlafaxine ER is the first listed.
NCT00401726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00401726 about?
NCT00401726 is a clinical study titled "Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program". The purpose of this study is to evaluate the effect of the Dialogues Time to Talk program in subjects treated with Venlafaxine Extended Release (ER). Dialogues Time to Talk Program is a patient management program, which aims to help patients achieve successful outcomes by reinforcing physician treat...
What is the current status of trial NCT00401726?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 537 participants. The study started on 2006-06. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00401726?
The interventions under investigation include: Venlafaxine ER (DRUG), Dialogues Time to Talk Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT00401726?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.